We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
(-13%)
Cap. Flow
-$118M
Cap. Flow
% of AUM
-3.94%
Top 10 Holdings %
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$40.3M |
| 2 |
argenx
ARGX
|
+$39.9M |
| 3 |
Revolution Medicines
RVMD
|
+$39.2M |
| 4 |
Immunovant
IMVT
|
+$29.2M |
| 5 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$68.3M |
| 2 |
Vir Biotechnology
VIR
|
+$48M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$46.2M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$35.7M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$33.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.21% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Illumina
ILMN
$34B
| – | – |
-149,060
| Closed | -$27.2M |
|
102
Quanterix
QTRX
$132M
| – | – |
-130,000
| Closed | -$2.93M |
|
|
TERN
103
PUT
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-1,075,000
| Closed | -$9.41M |
|
|
104
Vir Biotechnology
VIR
$1.81B
| – | – |
-1,958,264
| Closed | -$48M |
|
105
Viking Therapeutics
VKTX
$3.99B
| – | – |
-441,147
| Closed | -$6.31M |
|
|
VRNA
106
CALL
DELISTED
Verona Pharma
VRNA
| – | – |
-500,000
| Closed | -$675K |
|
107
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.8B
| – | – |
-150,000
| Closed | -$138K |
|
|
ITCI
108
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-245,800
| Closed | -$15.6M |
|
|
MRTX
109
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-200,000
| Closed | -$690K |
|
|
MRTX
110
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-719,103
| Closed | -$26M |
|
|
RETA
111
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-670,206
| Closed | -$68.3M |
|
|
ISEE
112
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-168,000
| Closed | -$6.61M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
LSERS
CAG
MCM
Perceptive Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $118M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.
- Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
- Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
- Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
- Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
- Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
- Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.
Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.